Adicet Bio Appoints Dr Julie Maltzman As Chief Medical Officer To Advance Clinical Development

Adicet Bio, Inc., is a clinical-stage biotech company specializing in allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The organization has announced the appointment of Dr Julie Maltzman as Chief Medical Officer, effective from January 13, 2025. In her new role, Dr. Maltzman will lead Adicet's clinical development strategy, which will focus on advancing its autoimmune and oncology pipeline. Dr. Maltzman brings over 20 years of experience in clinical development across oncology and autoimmune diseases, which includes all phases of drug development, regulatory approvals, and commercialization. 

She most recently served as Chief Medical Officer at IconOVir Bio, where she led clinical programs targeting refractory solid tumours. Previously, she was Vice President and Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech, where she played a pivotal role in the global registration and commercialization of Tecentriq+Avastin®. Dr. Maltzman co-chaired Roche’s Cancer Immunotherapy Committee, crafting an integrated strategic roadmap for cancer immunotherapy development. 

Chen Schor, President and Chief Executive Officer of Adicet Bio, said in a statement, “We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the clinical development of multiple products across therapeutic areas, notably in solid tumours and autoimmune diseases, from early-stage research to global approvals and commercialization, will be a big asset for Adicet as we advance our novel pipeline of allogeneic gamma delta CAR T cell therapies for multiple autoimmune and oncology indications.”

Mr Chen Schor added, “We’re at an exciting point where we are seeing significant momentum in our clinical trial enrollment efforts, with an increasing number of sites activated and patients enrolling in both the ADI-001 and ADI-270 programs. This progress highlights the promising potential of our therapies. Julie’s expertise will help position us well in our goal for continued success in the development and regulatory progress of these novel therapies for patients. We thank Dr Galimi for his contributions and wish him all the best in his future endeavours.” 

Her earlier roles include leading first-in-human monoclonal antibody trials for rheumatoid arthritis at Morphotek Inc. Her prior positions included holding key positions at Gilead and GlaxoSmithKline (GSK). Dr. Maltzman has a track record of designing and executing clinical trials that exceed enrollment goals, supporting regulatory submissions, and building medical functions that drive therapeutic adoption. Dr. Maltzman earned her M.D. from the University of Colorado, completed her Internal Medicine residency at the University of Chicago, and pursued a fellowship in Hematology/Oncology at the University of Pennsylvania.

Julie Maltzman, M.D., expressed her enthusiasm, saying, “I am extremely honoured and privileged to join the Adicet team during this pivotal time in the Company’s growth trajectory. Having worked on the development of several transformative therapies, I believe Adicet’s novel allogeneic gamma delta CAR T cell platform has life-changing potential for patients with various oncologic and autoimmune diseases. I am inspired by the opportunity to help lead our efforts to bring these therapies in development to the many patients around the globe who are in dire need of a potential new curative treatment approach.”